Prosecution Insights
Last updated: November 15, 2026
Application No. 18/696,808

POSITIVE AIRWAY PRESSURE SYSTEMS AND METHODS FOR DELIVERING AIR TO A PATIENT

Final Rejection §102§103§112
Filed
Mar 28, 2024
Priority
Oct 06, 2021 — provisional 63/253,027 +3 more
Examiner
SIPPEL, RACHEL T
Art Unit
3785
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sleepres LLC
OA Round
2 (Final)
52%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
427 granted / 813 resolved
-17.5% vs TC avg
Strong +58% interview lift
Without
With
+58.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
860
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Amendment This office action is responsive to the amendment filed on 9/16/26. As directed by the amendment: claims 1-3, 9, 15 and 18 have been amended, claims 16-17 and 19-20 have been canceled, and new claims 21-34 have been added. Thus, claims 1-15, 18 and 21-34 are presently pending in the application. Claim Objections Claims 15 and 31 are objected to because of the following informalities: Claims 15 (lines 8-9) and 31 (lines 11-12) recite “a treatment period,” suggested to be changed to --the treatment period-- for consistency. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-4 and 31-34 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 recites “an existing positive airway pressure system” in line 2, however it is unclear is this system is the same as the positive airway pressure system from claim 1 or a new and different system. Claims 4 and 31 limitations of “a memory component to modulate air flow” invokes 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. However, the written description fails to disclose the corresponding structure, material, or acts for performing the entire claimed function and to clearly link the structure, material, or acts to the function. The disclosure is devoid of any structure that performs the function in the claim. Therefore, the claim is indefinite and is rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. Applicant may: (a) Amend the claim so that the claim limitation will no longer be interpreted as a limitation under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph; (b) Amend the written description of the specification such that it expressly recites what structure, material, or acts perform the entire claimed function, without introducing any new matter (35 U.S.C. 132(a)); or (c) Amend the written description of the specification such that it clearly links the structure, material, or acts disclosed therein to the function recited in the claim, without introducing any new matter (35 U.S.C. 132(a)). If applicant is of the opinion that the written description of the specification already implicitly or inherently discloses the corresponding structure, material, or acts and clearly links them to the function so that one of ordinary skill in the art would recognize what structure, material, or acts perform the claimed function, applicant should clarify the record by either: (a) Amending the written description of the specification such that it expressly recites the corresponding structure, material, or acts for performing the claimed function and clearly links or associates the structure, material, or acts to the claimed function, without introducing any new matter (35 U.S.C. 132(a)); or (b) Stating on the record what the corresponding structure, material, or acts, which are implicitly or inherently set forth in the written description of the specification, perform the claimed function. For more information, see 37 CFR 1.75(d) and MPEP §§ 608.01(o) and 2181. Any remaining claims are rejected as being dependent on a rejected base claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 4-11, 15, 18, 21-23, 28-29 and 31-34 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Colbaugh et al. (2019/0183417). Regarding claim 1, in fig. 1 Colbaugh discloses a method for delivering air to a patient throughout the patient's respiratory cycle [0016], the method comprising: providing a positive airway pressure system (via pressure generator 140), the system including a flow generator 140 and conduit 182 having an outlet configured to connect to a patient's respiratory system (outlet connected to interface appliance 184); applying an inspiratory positive airway pressure through the outlet during an inspiration phase of the patient's respiratory cycle [0019] over a treatment period (at least two breaths); and applying an expiratory positive airway pressure through the outlet during an expiration phase of the patient's respiratory cycle [0019] over the treatment period; wherein the inspiratory positive airway pressure is less than the expiratory positive airway pressure [0019] resulting in improved comfort of the patient during the treatment period while maintaining a prescribed pressure therapy ([0042] comfort is provided by continuing to provide less pressure to a user during inhalation until an obstruction for example is reaches, such that too much pressure is not provided, which may disturb sleep); wherein the treatment period extends throughout a time when the patient is asleep (the patient is asleep during use). Regarding claim 4, Colbaugh discloses that the positive airway pressure system includes a computer with a processor 110 for executing instructions stored in a memory 130 component to modulate air flow through the outlet such that the expiratory positive airway pressure is greater than the inspiratory positive airway pressure [0004][0025]. Regarding claim 5, Colbaugh discloses that the patient sets the inspiratory positive airway pressure (via user interface 120 [0026]). Regarding claim 6, Colbaugh discloses that the patient sets the expiratory positive airway pressure (via user interface 120 [0026]). Regarding claim 7, Colbaugh discloses that the method further comprising setting a maximum inspiratory positive airway pressure (recommended IPAP level [0042]) and a maximum expiratory positive airway pressure (recommended EPAP level [0042]); wherein the patient sets the inspiratory positive airway pressure at or below the maximum inspiratory positive airway pressure [0042][0026]. Regarding claim 8, Colbaugh discloses that the patient sets the expiratory positive airway pressure at or below the maximum expiratory positive airway pressure [0004][0038]. Regarding claim 9, Colbaugh discloses that the inspiratory positive airway pressure is lower when the patient falls asleep and gradually increases over the treatment period (the IPAP changes throughout the sleep period of a patient and therefore an increase occurs as needed [0053]). Regarding claim 10, Colbaugh discloses that the inspiratory positive airway pressure is determined based on a patient parameter [0028][0041]. Regarding claim 11, Colbaugh discloses that the inspiratory positive airway pressure is determined based on an ambient condition [0028-0030]. Regarding claim 15, in fig. 1 Colbaugh discloses positive airway pressure system comprising: a flow generator 140; a conduit 182 operably connected to the flow generator, the conduit having an outlet configured to connect to a patient's respiratory system (outlet connected to interface appliance 184); wherein the flow generator provides an inspiratory positive airway pressure through the outlet during each inspiration phase of the patient's respiratory cycle over a treatment period extending through a time when the patient is asleep ([0019][0042-0043] over the course of multiple breathing cycles and challenges until a particular condition occurs) and an expiratory positive airway pressure through the outlet during each expiration phase of the patient's respiratory cycle over a treatment period [0019]; the positive airway pressure system further includes a passive air flow resistor (a portion of the conduit 182 due to friction) to reduce air flow through the outlet during the inspiration phase of the patient's respiratory cycle proportionally to air flow through the passive air flow resistor without affecting the expiratory positive airway pressure providing that the inspiratory positive airway pressure is less than the expiratory positive airway pressure ([0019][0042-0043]) wherein the passive air flow resistor has no moving parts (the tubing has no moving parts). Regarding claim 18, Colbaugh discloses that a portion of the conduit is configured to function as the air flow resistor (a portion of the conduit 182 due to friction). Regarding claim 21, Colbaugh discloses that during each expiration phase of the patient's respiratory cycle, the expiratory positive airway pressure begins equal to the inspiratory positive airway pressure and increases during the expiration phase of the patient's respiratory cycle up to a maximum expiratory positive airway pressure greater than the inspiratory positive airway pressure (this will occur due to the fact that Colbaugh discloses that the inspiratory positive air pressure is greater than the expiratory positive airway pressure). Regarding claim 22, Colbaugh discloses that during each inspiration phase of the patient's respiratory cycle, the inspiratory positive airway pressure begins equal to the expiratory positive airway pressure and decreases during the inspiration phase of the patient's respiratory cycle down to a minimum inspiratory positive airway pressure less than the expiratory positive airway pressure (this will occur due to the fact that Colbaugh discloses that the inspiratory positive air pressure is greater than the expiratory positive airway pressure). Regarding claim 23, Colbaugh discloses that the inspiratory positive airway pressure increases over multiple treatment periods ([0052] during various portions of a user’s sleep the inspiratory positive airway pressure increases due to a particular determination or condition). Regarding claim 28, Colbaugh discloses that the passive air flow resistor is integrally formed (via tubing 182). Regarding claim 29, Colbaugh discloses that the passive air flow resistor is positioned inline between the flow generator and outlet (see tubing 182). Regarding claim 31, in fig. 1 Colbaugh discloses a positive airway pressure system comprising: a conduit 182 having an outlet configured to connect to a patient's respiratory system (outlet connected to interface appliance 184); a flow generator 140 including a fan [0031], the flow generator operably connected to the conduit such that changing the speed of the fan affects pressure provided to the patient's respiratory system by the conduit [0017][0019][0031]; a computer with a processor 110 for executing instructions stored in a memory component 130 to modulate the speed of the fan [0004][0025][0031]; wherein the flow generator provides an inspiratory positive airway pressure through the outlet during each inspiration phase of the patient's respiratory cycle [0019] over a treatment period (at least two breaths) extending through a time when the patient is asleep (the patient is asleep during use) and an expiratory positive airway pressure through the outlet during each expiration phase of the patient's respiratory cycle over a treatment period [0019]; and wherein the inspiratory positive airway pressure is less than the expiratory positive airway pressure [0019]. Regarding claim 32, Colbaugh discloses that during each expiration phase of the patient's respiratory cycle, the expiratory positive airway pressure begins equal to the inspiratory positive airway pressure and the computer increases the speed of the fan throughout the expiration phase of the patient's respiratory cycle until a maximum expiratory positive airway pressure greater than the inspiratory positive airway pressure is achieved (this will occur due to the fact that Colbaugh discloses that the inspiratory positive air pressure is greater than the expiratory positive airway pressure). Regarding claim 33, Colbaugh discloses that during each inspiration phase of the patient's respiratory cycle, the inspiratory positive airway pressure begins equal to the expiratory positive airway pressure and the computer decreases the speed of the fan throughout the inspiration phase of the patient's respiratory cycle until a minimum inspiratory positive airway pressure less than the expiratory positive airway pressure is achieved (this will occur due to the fact that Colbaugh discloses that the inspiratory positive air pressure is greater than the expiratory positive airway pressure). Regarding claim 34, Colbaugh discloses that the computer is programmed to automatically increase the inspiratory positive airway pressure over multiple treatment periods ([0052] during various portions of a user’s sleep the inspiratory positive airway pressure automatically increases due to a particular determination or condition). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Colbaugh, as applied to claim 1 above, in further view of Truitt et al. (6,915,705). Regarding claim 2, Colbaugh is silent regarding that the positive airway pressure system further includes a passive air flow resistor with no moving parts, wherein the passive air flow resistor reduces air flow through the outlet during the inspiration phase of the patient's respiratory cycle proportionally to air flow through the passive air flow resistor thereby providing that the expiratory positive airway pressure is greater than the inspiratory positive airway pressure. However, in fig. 1 and 6A-7 Truitt teaches a positive airway pressure system further includes a passive air flow resistor 74 with no moving parts (Col. 6, ll. 41-42) attached to flow sensing structure 72. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s sensor 142 with an air flow sensor having an air flow resistor, as taught by Truitt, for the purpose of determining flow through the system. The modified Colbaugh discloses that the passive air flow resistor (74 Truitt) reduces air flow through the outlet during the inspiration phase of the patient's respiratory cycle proportionally to air flow through the passive air flow resistor (due to the openings in the resistor 74, Truitt) thereby providing that the expiratory positive airway pressure is greater than the inspiratory positive airway pressure (since Colbaugh already teaches expiratory positive airway pressure is greater than the inspiratory positive airway pressure). Claims 12-14 are rejected under 35 U.S.C. 103 as being unpatentable over Colbaugh, as applied to claim 1 above, in further view of Hakim et al. (“Expiratory and inspiratory positive airway pressures in obstructure sleep apnea: how much pressure is necessary? A different point of view” 2015). Regarding claim 12, Colbaugh is silent regarding that the inspiratory positive airway pressure is substantially zero. However, Hakim teaches an inspiratory positive airway pressure is substantially zero (Fig. 2, Page 135 second column, bottom half of page, starting at the first complete sentence). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s inspiratory pressure with an inspiratory pressure of substantially zero, for the purpose of treating obstructive sleep apnea (abstract) and preventing upper airway collapse at the end of expiration (Page 135, right column). Regarding claim 13, Colbaugh is silent regarding that the expiratory positive airway pressure is between 4 and 20 cm H20. However, Hakim teaches expiratory positive airway pressure is between 4 and 20 cm H20 (Fig. 2, Page 135 second column, bottom half of page, starting at the first complete sentence). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s expiratory positive airway pressure with an expiratory positive airway pressure between 4 and 20 cm H20, for the purpose of treating obstructive sleep apnea (abstract) and preventing upper airway collapse at the end of expiration (Page 135, right column). Regarding claim 14, Colbaugh is silent regarding that an average negative pressure provided by the patient during inspiration is determined and the inspiratory positive airway pressure is below the average negative pressure. However, Hakim teaches that an average negative pressure provided by the patient during inspiration is determined and the inspiratory positive airway pressure is below the average negative pressure (Fig. 2, upper right figure, Page 135 second column, bottom half of page, starting at the first complete sentence, 0 cmH2O of pressure is provided during inhalation and an average of negative 5 cmH2O (since the pressure starts at 0 and moves towards -10) is provided by the patient during inhalation). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s inspiratory positive airway pressure to be below the average negative pressure, for the purpose of treating obstructive sleep apnea (abstract) and preventing upper airway collapse at the end of expiration (Page 135, right column). Claim 24 is rejected under 35 U.S.C. 103 as being unpatentable over Colbaugh, as applied to claim 1 above, in further view of Mersmann et al. (2015/0335839). Regarding claim 24, Colbaugh is silent regarding a step of determining that a patient's tidal volume is large and gradually lowering the inspiratory positive airway pressure to avoid hyperventilation. However, Mersmann teaches a step of determining that a patient's tidal volume is large and gradually (compared to a larger decrease) lowering the inspiratory positive airway pressure to avoid hyperventilation [0052]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s method with the addition of a step of lowering the IPAP when the tidal volume is large, as taught by Mersmann, for the purpose of providing safety to the user. Claim 25 is rejected under 35 U.S.C. 103 as being unpatentable over Colbaugh, as applied to claim 1 above, in further view of Brittelli et al. (2022/0152327). Regarding claim 25, Colbaugh is silent regarding steps of measuring atmospheric pressure; and reducing inspiratory positive airway pressure, expiratory positive airway pressure, or both inspiratory positive airway pressure and expiratory positive airway pressure if the atmospheric pressure is below a predetermined level. However, Brittelli teaches steps of measuring atmospheric pressure [0038]; and reducing inspiratory positive airway pressure, expiratory positive airway pressure, or both inspiratory positive airway pressure and expiratory positive airway pressure if the atmospheric pressure is below a predetermined level ([0046] the pressure delivered to a user will be decreased when the atmospheric pressure increases, yet is still below a predetermined level based on altitude). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s method with the steps of measuring atmospheric pressure; and reducing inspiratory positive airway pressure, expiratory positive airway pressure, or both inspiratory positive airway pressure and expiratory positive airway pressure if the atmospheric pressure is below a predetermined level, as taught by Brittelli, for the purpose of providing safety to the user. Claims 26-27 and 30 are rejected under 35 U.S.C. 103 as being unpatentable over Colbaugh, as applied to claim 15 and 29 above, respectively, in further view of Truitt et al. (6,915,705). Regarding claim 26, Colbaugh is silent regarding that the passive air flow resistor includes an inlet side and an outlet side with an air channel defined through the air flow resistor from the inlet side to the outlet side and a resistive element is positioned to interrupt the air channel. However, in fig. 1 and 6A-7 Truitt teaches a passive air flow resistor 74 that includes an inlet side (at 76) and an outlet side (at 78) with an air channel (extending from inlet to outlet) defined through the air flow resistor from the inlet side to the outlet side and a resistive element (formed by spokes 100) is positioned to interrupt the air channel. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s sensor 142 with an air flow sensor having an air flow resistor, as taught by Truitt, for the purpose of determining flow through the system. Regarding claim 27, the modified Colbaugh discloses that the resistive element defines a plurality of holes (98 Truitt). Regarding claim 30, the modified Colbaugh is silent regarding that the passive air flow resistor includes an inlet side nearest to the flow generator and an outlet side nearest to the outlet with an air channel defined through the air flow resistor from the inlet side to the outlet side and a resistive element is positioned to interrupt the air channel. However, in fig. 1 and 6A-7 Truitt teaches a passive air flow resistor 74 that includes an inlet side (at 76) nearest to the flow generator and an outlet side (extending from inlet to outlet) nearest to the outlet with an air channel defined through the air flow resistor from the inlet side to the outlet side and a resistive element (formed by spokes 100) is positioned to interrupt the air channel. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Colbaugh’s sensor 142 with an air flow sensor having an air flow resistor, as taught by Truitt, for the purpose of determining flow through the system. Allowable Subject Matter Claim 3 would be allowable if rewritten to overcome the rejections under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Response to Arguments Applicant's arguments filed 9/16/26 have been fully considered but they are not persuasive. Applicant argues on page 14 that Colbaugh’s challenges that lower IPAP below EPAP are not for treatment and only last one or more breathing cycles. This argument is not taken well since Colbaugh’s challenges do occur during treatment and are part of the treatment for the user to provide the appropriate amount of IPAP for a user during a sleep period. Further, the claim language does not preclude a treatment period of multiple breathing cycles when the challenges occur. Applicant argues on page 14 that the challenges do not provide comfort as claimed. Examiner disagrees since providing less pressure to a sleeping user does provide comfort when a higher IPAP may wake a user, particularly before a breathing disorder is identified over the course of more than one breathing cycle. Applicant’s arguments, see pages 17-18, filed 9/16/26, with respect to the rejection of claim 2 under Colbaugh in view of Zdrojkowski have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground of rejection is made in view of Colbaugh in view of Truitt. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHEL T SIPPEL whose telephone number is (571)270-1481. The examiner can normally be reached M-F 9:00-5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Timothy Stanis can be reached at (571) 272-5139. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RACHEL T SIPPEL/Primary Examiner, Art Unit 3785
Read full office action

Prosecution Timeline

Mar 28, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §102, §103, §112
Sep 16, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758731
DIAPHRAGM NASAL BREATHING REGULATOR
2y 6m to grant Granted Oct 13, 2026
Patent 12752067
AUTO IDENTIFICATION OF PATIENT INTERFACE BASED ON CHANGES IN A PRESSURE SUPPORT SYSTEM
2y 9m to grant Granted Oct 06, 2026
Patent 12746348
APPARATUS FOR USE IN AEROSOL DELIVERY
2y 9m to grant Granted Sep 29, 2026
Patent 12721773
INTERMETATARSAL SPACE VIBRATOR
3y 3m to grant Granted Sep 01, 2026
Patent 12721960
DEVICE FOR NASAL DELIVERY OF A FLUID PRODUCT
2y 8m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
52%
Grant Probability
99%
With Interview (+58.2%)
Moderate
PTA Risk
Based on 813 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month